

Index

A

ABORTION

- spontaneous
- as risk factor for gestational diabetes, 22, 25
- in pregnant rhesus monkeys with fetally implanted insulin pumps, 36

ADIPOSE TISSUE

- thoracic cavity
- in hyperinsulinemic and control rhesus monkey fetuses, 39–40

AGE

- fetal
- ultrasound examination in gestational diabetic and insulin-dependent diabetic women and, 47–49
- of gestational diabetic women
- and pancreatic β -cell and somatic development in infants of, 1–6
- maternal
- incidence of gestational diabetes and, 15, 56
- screening for gestational diabetes and, 22

ALANINE

- oral
- plasma glucagon response in pregnancy to, 68–69

AMNIOTIC FLUID

- insulin
- gestational diabetes and, 5

ANIMALS. See also Lambs; Rats

- models for gestational diabetes, 28–31, 125
- primate fetus, effects of hyperinsulinemia in, 36–40

ANTIBODIES

- to insulin
- diabetic pregnancy and, 94–96
- islet cell, of gestational diabetic mothers
- pancreatic β -cell and somatic development in infants of, 1–6

APGAR SCORES

- of infants of mothers with glucose intolerance during pregnancy, 62–64

APOPROTEINS

- maternal levels during pregnancy, infant birth size and, 71–76

B

BLOOD GLUCOSE

- antenatal screening of, 17–20
- control
- and diet vs. insulin in gestational diabetes, 101–104
- and insulin levels in gestational diabetic rats, 28–31

BREAST FEEDING

- after gestational diabetes, 125

C

CARBOHYDRATE

- intolerance
- diagnosis of gestational diabetes and, 8–11
- loading
- in offspring of gestational diabetics, 119–122
- metabolism
- in gestational diabetes, 66–69
- in pregnant animals, as model of gestational diabetes, 29–30

CELLS

- hyperplasia
- fetal hyperinsulinemia and, 40

CESAREAN SECTION

- incidence
- in gestational diabetes and controls, 55–59, 62, 121–122
- in rhesus monkeys with fetally implanted insulin pumps, 36

CHLORPROPAMIDE

- therapy, compared with diet therapy in follow-up study of gestational diabetes, 106–110

CONGENITAL ANOMALIES

- in infants of mothers with gestational diabetes, 9, 16, 124–125
- in infants of mothers with glucose intolerance during pregnancy, 62–64
- in previous children
- screening for gestational diabetes and, 22, 25

CORTISOL

- carbohydrate metabolism during pregnancy and, 69

C-PEPTIDE

- immunoreactivity, umbilical cord correlation of infant birth weight with, 38–39
- response to breakfast in women with gestational diabetes
- diet and insulin therapy and, 88–92

D

DIABETES MELLITUS. See also Gestational diabetes mellitus

- development, gestational diabetes and, 106–110, 126
- diagnosis, antenatal blood glucose screening tests and, 17–20

DIET

- compared with diet and chlorpropamide therapy in follow-up study of women with gestational diabetes, 106–110
- compared with insulin or insulin and diet in gestational diabetes, 97–100, 101–104
- intrapartum events and fetal outcome and, 57, 58
- and metabolic profiles of women with gestational diabetes, 88–92

E

ETHNICITY

- incidence of gestational diabetes and, 8–11

EXERCISE

- by diabetic and nondiabetic pregnant patients
- hormonal responses to, 78–80
- gestational diabetes and, 125

F

FAMILY HISTORY

- risk factors for gestational diabetes and, 25
- screening for gestational diabetes and, 22–23

FETUS

- death
- gestational diabetes and, 14–16
- management of gestational diabetes and, 24

- diabetic rat
 - relationship between maternal and fetal fuels and placental glucose transfer in, 42–45
- of gestational diabetics and controls
 - intrapartum characteristics of, 57
- of gestational diabetics and insulin-dependent diabetics
 - growth delay in, 47–49
- growth
 - maternal lipoproteins, apoproteins, fuels, hormones, clinical chemistries, and weight and, 71–76
- lamb
 - effects of perturbations of fuels in, 32–35
- large for gestational age
 - screening for gestational diabetes and, 22
- macrosomia
 - gestational diabetes and, 124–125
- outcome
 - management of gestational diabetes and, 55–59
- perinatal loss
 - gestational diabetes and impaired glucose tolerance and, 121
- primate
 - effects of hyperinsulinemia in, 36–40
- streptozocin-diabetic rat
 - long-term effects of diabetes on, 116–118

G

GENES

- phenotypic and genotypic characteristics of postpartum gestational diabetics and abnormal glucose tolerance, 111–114

GEOGRAPHY

- incidence of gestational diabetes and, 8–11

GESTATIONAL DIABETES MELLITUS

- animal models for, 28–31, 125
 - effects of hyperinsulinemia in primate fetus, 36–40
- antenatal blood glucose screening and, 17–20
- classification of, 85–86
- detection of, 124
- early growth delay and, 47–49
- etiology and pathophysiology of, 66–69
- exercise and, 125
- geographic, ethnic, and racial variations in incidence of, 8–11
- glucagon secretion and, 67–69
- hyperinsulinemia in primate fetus and, 36–40
- incidence, maternal characteristics, and perinatal outcome and, 13–16
- insulin resistance in, 69
- insulin therapy in
 - immunogenicity of new insulins and, 94–96
 - therapeutic results of, 97–100
- intrapartum characteristics of control subjects and patients with, 57
- long-range implications for mother, 106–110

- long-term effects on obesity and glucose tolerance in offspring, 119–122
- management
 - evaluation of diet vs. insulin and diet, 101–104
 - fetal outcome and, 55–59
 - perinatal mortality and, 24
- maternal age, weight, insulin secretion, HLA antigens, and islet cell antibodies
 - pancreatic B-cell and somatic development of infant related to, 1–6
- maternal characteristics in, 56
- maternal lipoproteins, apoproteins, fuels, hormones, clinical chemistries and weight in
 - infant birth size and, 71–76
- maternal metabolism in
 - effect of diet and insulin on, 88–92
- and metabolic and therapeutic assessment by isocaloric meal tolerance tests, 81–86
- neonatal morbidities in infants of mothers with, 61–64
- obstetric and perinatal management of, 124–125
- pathogenesis of, 30–31
- perturbations of fetal fuels in ovine pregnancy as model of, 32–35
- phenotypic and genotypic maternal characteristics correlated with abnormal postpartum glucose tolerance, 111–114
- prognosis for, 126
- recommendations, 123–126
- relationship between maternal and fetal fuels and placental glucose transfer in rats with, 42–45
- risk factors for
 - screening tests and, 22–23, 24–27
- screening
 - antenatal blood glucose tests and, 17–20
 - clinical application and cost analysis in high risk and general population, 24–27
 - retesting timing and criteria, 21–23

GLUCAGON

- secretion in pregnancy, pathogenesis of gestational diabetes and, 67–69

GLUCOSE

- infused in fetal lambs, 32–35
- placental transfer in rats with maternal diabetes
 - maternal and fetal fuels and, 42–45
- plasma levels in gestational diabetes
 - diet and insulin therapy and, 88–92

GLUCOSE CHALLENGE TESTS

- gestational diabetes screening and, 24–27
- timing and criteria for retesting, 21–23

GLUCOSE INTOLERANCE. See also Gestational diabetes mellitus

- diagnosis of gestational diabetes mellitus and, 2
- neonatal morbidities in infants of mothers with, 61–64
- during pregnancy
 - long-term effects on obesity and glucose tolerance in offspring, 119–122

GLUCOSE TOLERANCE

- abnormal during first year postpartum in gestational diabetics
 - correlations with phenotypic and genotypic characteristics, 111–114
- diagnosis of gestational diabetes and, 124
- exercise in diabetic and nondiabetic pregnancy and, 78–80
- in follow-up studies of women with gestational diabetes, 106–110
- incidence of gestational diabetes and, 13
- in offspring of mothers with gestational diabetes, 119–122

GLUCOSE TOLERANCE TESTS

- diagnosis of gestational diabetes and, 8–11
- intravenous, in follow-up studies of women with gestational diabetes, 106–110
- oral
 - antenatal blood glucose screening and, 18–20
 - diagnosis of gestational diabetes and, 124
 - in gestational diabetes, 66–69
 - screening for gestational diabetes and, 24–27

GLYCOSURIA

- history of, screening for gestational diabetes and, 22

GROWTH

- fetal
 - delay in diabetic pregnancies, 47–49

GROWTH FACTORS

- insulin-like
 - birth weights of infants of diabetic mothers and, 36

H

HEART

- congenital abnormality
 - incidence of gestational diabetes and, 9

HEMOGLOBIN A

- maternal
 - birth weight of infants of diabetic mothers and, 38
 - diabetes control during pregnancy and, 48

HEREDITY

- abnormal glucose tolerance during first year postpartum in gestational diabetics and, 111–114
- and long-term effect of diabetes and pregnancy in rats, 116–118

HLA ANTIGENS

- of gestational diabetic mothers
 - and pancreatic β -cell and somatic development in infants of, 1–6

HLA TYPING

in gestational diabetes postpartum
correlation with abnormal glucose tolerance, 111–114

HORMONES

during pregnancy
related to infant birth size, 71–76
responses to exercise in diabetics and nondiabetics, 78–80

HYDROCEPHALUS

incidence of gestational diabetes and, 9

HYPERBILIRUBINEMIA

in infants of mothers with glucose intolerance during pregnancy, 62–64

HYPERGLYCEMIA

in glucose-infused fetal lambs, 32–35
maternal
fetal hyperinsulinemia and fetal macrosomia and morbidity and, 99–100

HYPERINSULINEMIA

in chronically catheterized glucose-infused fetal lambs, 34–35
in primate fetus
as model of gestational diabetes, 36–40

HYPERPLASIA

cellular
fetal hyperinsulinemia and, 40

HYPOGLYCEMIA

in infants of mothers with glucose intolerance during pregnancy, 62–64

HYPOXIA

in utero
fetal death and, 39

I**IMMUNOGENICITY**

of new insulins
diabetic pregnancy and, 94–96

INFANTS

birth size
related to maternal lipoproteins, apoproteins, fuels hormones, clinical chemistries, and body weight, 71–76
birth weights
gestational diabetes and, 16, 57
risk factors for gestational diabetes and, 25
characteristics
diet therapy vs. diet and insulin therapy in gestational diabetes and, 102–104
death
management of gestational diabetes and, 97–100
of mothers with gestational diabetes morbidities in, 61–64
obesity and glucose intolerance in, 119–122, 126
pancreatic β -cell and somatic development of, 1–6

INSULIN

degradation in pregnancy
glucose intolerance and, 67
-dependent pregnant diabetics
fetal early growth delay in, 47–49
effect on metabolic profiles of women with gestational diabetes, 88–92
-glucose ratio in women with gestational diabetes
diet and exercise and, 91
infusion in fetal lambs, 34–35
maternal and fetal
in gestational diabetes, 36
new
during diabetic pregnancy, 94–96
in pregnant streptozocin-diabetic rats
relationship between maternal and fetal fuels and placental glucose transfer and, 42–45
requirements
exercise in diabetic and nondiabetic pregnancy and, 78–80
in pregnant rats, as model for gestational diabetes, 29
resistance
in normal pregnancy and gestational diabetes, 69
secretion in gestational diabetic mothers
pancreatic β -cell and somatic development of infants and, 1–6
therapy in gestational diabetes, 97–100
vs. diet therapy, 101–104
intrapartum and fetal outcome and, 58

INSULIN PUMP

implantation in fetal rhesus monkey, 36–40

K**KIDNEYS**

pyelonephritis or urinary tract infections
screening for gestational diabetes and, 22

L**LAMBS**

fetal
perturbations of fetal fuels during pregnancy and, 32–35

LIPOPROTEINS

maternal, during pregnancy
related to infant birth size, 71–76

M**MACROSOMIA**

fetal, in gestational diabetes
insulin therapy and, 99–100

MEAL TOLERANCE TESTS

isocaloric
metabolic and therapeutic assessment of gestational diabetes by, 81–86

METABOLISM

of chronically catheterized glucose-infused fetal lambs, 32–35
of gestational diabetics
effect of diet and insulin on, 88–92
pancreatic β -cell and somatic development of infants of, 1–6
of pregnant diabetic rats
relationship between maternal and fetal fuels and placental glucose transfer in, 42–45

MONKEYS

fetal rhesus
effects of hyperinsulinemia in, 36–40

MORTALITY

diabetes
infant mortality rates related to, 9
fetal
hyperinsulinemia in rhesus monkey fetuses and, 36, 40
infant
incidence of gestational diabetes and, 9
perinatal, in gestational diabetes, 14–16, 57
insulin therapy vs. diet vs. diet and insulin and, 97–100
management of pregnancy and, 24

N**NATIONAL FETAL MORTALITY SURVEY, 14–16****NATIONAL NATALITY SURVEY, 14–16****NOREPINEPHRINE**

plasma levels in pregnant diabetic and nondiabetic women
exercise and, 78–80

O**OBESITY**

gestational diabetes and, 56
fetal outcome and, 58, 59
in follow-up study, 106–110
metabolic and therapeutic assessment by isocaloric meal tolerance tests and, 81–86
as risk factor, 25
screening tests and, 22
in offspring of mothers with gestational diabetes or impaired glucose tolerance during pregnancy, 119–122

OXYGEN

uptake, delivery and consumption in fetal lambs
chronic glucose infusion and, 33–35

P**PANCREAS**

of animal models of gestational diabetes, 28–31

- fetal
 gestational diabetes and, 36
 of offspring of gestational diabetic mothers
 β -cell and somatic development, 1–6
 long-term effects on third-generation, 116–118
- PIMA INDIANS**
 gestational diabetes and impaired glucose tolerance during pregnancy in
 long-term effects on obesity and glucose tolerance in offspring of, 119–122
 prevalence of, 11
- PLACENTA**
 in gestational diabetes, 4–5, 36
 glucose transfer in rats with maternal diabetes
 relationship between maternal and fetal fuels and, 42–45
- PLASMA**
 fasting glucagon
 gestational diabetes and, 67–69
 fasting glucose
 diagnosis of gestational diabetes and, 3
 fetal hormones
 in rhesus monkey fetuses with insulin pump implants, 36–40
 glucose assays
 in study of neonatal morbidities in gestational diabetes, 61–64
 glucose control in gestational diabetes
 relationship to perinatal mortality and morbidity, 97–98
 glucose, epinephrine, glucagon, free fatty acids, and norepinephrine
 exercise in diabetic and nondiabetic pregnancy and, 78–80
 glucose, insulin, and 3-hydroxybutyrate in gestational diabetes
 diet and insulin therapy and, 88–92
 C-peptide immunoreactivity
 umbilical cord, correlation with infant birth weight, 38–39
- POLYCYTHEMIA**
 in infants of mothers with glucose intolerance during pregnancy, 62–64
- POLYHYDRAMINIOS**
 as risk factor for gestational diabetes, 25
 screening for gestational diabetes and, 22
- PREECLAMPSIA**
 gestational diabetes and, 57
- PREGNANCY**
 antenatal blood glucose screening in, 17–20
 complications in obstetrical history
 screening for gestational diabetes and, 22–23
 infant birth size related to maternal lipoproteins, apoproteins fuels, hormones, clinical chemistries, and weight, 71–76
 ovine
 effects of perturbations of fetal fuels in, 32–35
- rat
 as model for gestational diabetes, 28–31
 response to isocaloric meal tolerance tests during
 compared with gestational diabetes, 81–86
- PREGNANCY, DIABETIC.** See also Gestational diabetes mellitus
 consequences of perturbations of fetal fuels in lambs and, 32–35
 fetal growth delay in, 47–49
 hormonal responses to exercise in, 78–80
 insulin therapy during
 new insulins and, 94–96
 in rats
 relationship between maternal and fetal fuels and placental glucose transfer in, 42–45
- PREMATURITY**
 gestational diabetes and, 57
-
- R**
-
- RACE**
 incidence of gestational diabetes mellitus and, 8–11, 15, 56
- RATS**
 as animal model for gestational diabetes, 28
 maternal diabetes in
 relationship between maternal and fetal fuel and placental glucose transfer in, 42–45
 streptozocin-diabetic, pregnant
 long-term effect on offspring of, 116–118
-
- S**
-
- SEX**
 of infants of mothers with and without glucose
 intolerance during pregnancy, 63, 64
- SPINA BIFIDA**
 incidence of gestational diabetes and, 9
- STREPTOZOCIN DIABETES**
 in pregnant rats
 long-term effect on offspring of, 116–118
 relationship between maternal and fetal fuels and placental glucose transfer in, 42–45
-
- T**
-
- TERATOGENESIS**
 fuel-mediated
 gestational diabetes and, 6
- THORACIC CAVITY**
 adipose tissue in hyperinsulinemic and control rhesus fetus, 39–40
- TISSUE**
 adipose, thoracic cavity
 in hyperinsulinemic and control rhesus fetuses, 39–40
- TOXEMIA**
 history of
 screening for gestational diabetes and, 22
- TRAUMA**
 birth
 in infants of mothers with glucose intolerance during pregnancy, 62–64
- TRIGLYCERIDES**
 oral
 plasma glucagon levels in normal and gestational diabetic pregnant women, 68
- TWINS**
 fetal lambs
 effects of perturbations of fetal fuels in, 32–35
-
- U**
-
- ULTRASOUND**
 growth delay in gestational diabetes and insulin-dependent diabetes and, 47–49
- UMBILICAL CORD**
 plasma C-peptide immunoreactivity
 correlation of human infant birth weight with, 38–39
-
- V**
-
- VAGINA**
 monilial vaginitis
 as risk factor for gestational diabetes, 25
-
- W**
-
- WEIGHT**
 birth
 gestational diabetes and, 57, 62–64, 120
 maternal hemoglobin A and insulin-like growth factors in diabetics and, 38
 maternal, screening for gestational diabetes and, 22
 gestational diabetic mothers
 pancreatic β -cell and somatic development in infants and, 1–6
 maternal
 incidence of gestational diabetes and, 15–16
 infant birth size and, 71–76
 response to isocaloric meal tolerance tests and, 81–86